Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for a severe type of asthma, pulmonary arterial hypertension and inflammatory bowel disease, this IPO could be particularly appealing to investors. However, despite the promise associated with this biotech, there are also a number of potential problems that prospective investors should be aware of. For more, CLICK HERE.
A Promising Biotech IPO – And Its Potential Problems
Tags:BiotechBiotech InvestmentsBiotech StocksGossamer BioInvestingIPOProspective Investorsstock market